Literature DB >> 28884611

An Evaluation of the Activated Partial Thromboplastin Time Waveform.

Takeshi Matsumoto1, Hideo Wada2, Naoki Fujimoto2, Junki Toyoda2, Yasunori Abe2, Kohshi Ohishi1, Yoshiki Yamashita3, Makoto Ikejiri4, Kei Hasegawa4, Kei Suzuki5, Hiroshi Imai5, Kaname Nakatani4, Naoyuki Katayama3.   

Abstract

The activated partial thromboplastin time (APTT) waveform includes several parameters that are related to various underlying diseases. The APTT waveform was examined in various diseases. Regarding the pattern of APTT waveform, a biphasic pattern of the first or second derivative curve (DC) was observed in patients with hemophilia and patients positive for antiphospholipid (aPL) antibodies or coagulation factor VIII (FVIII) inhibitors. The time of the first and second DC and fibrin formation at 1/2 height were prolonged in patients with hemophilia, patients with inhibitors, patients positive for aPL, patients treated with anti-Xa agents, and patients with disseminated intravascular coagulation (DIC). These values all tended to decrease in pregnant women (at 28-36 weeks' gestation). The height of the second derivative peak 1 was significantly lower in patients with hemophilia, patients with FVIII inhibitors, patients positive for aPL, patients treated with anti-Xa agents, and patients with DIC; these values tended to be significantly higher in pregnant women. The height of the first DC was significantly lower in patients who were positive for FVIII inhibitors and was significantly higher in patients treated with anti-Xa agents and pregnant women. The height of the first and second DC was useful for the analysis of hemophilia, FVIII inhibitor, and aPL.

Entities:  

Keywords:  APTT; anticoagulant; biphasic waveform; hemophilia; waveform

Mesh:

Substances:

Year:  2017        PMID: 28884611      PMCID: PMC6714873          DOI: 10.1177/1076029617724230

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  19 in total

1.  A study of atypical APTT derivative curves on the ACL TOP coagulation analyser.

Authors:  C Solano; P Zerafa; R Bird
Journal:  Int J Lab Hematol       Date:  2011-02       Impact factor: 2.877

2.  Prognostic implications of a biphasic waveform for APTT analysis in a district general hospital.

Authors:  G Mair; S Dunhill; C Tiplady
Journal:  Int J Lab Hematol       Date:  2008-12       Impact factor: 2.877

3.  New quantitative aPTT waveform analysis and its application in laboratory management of haemophilia A patients.

Authors:  M Milos; D Coen Herak; S Zupancic-Salek; R Zadro
Journal:  Haemophilia       Date:  2014-10-02       Impact factor: 4.287

4.  Clot waveform analysis in patients with haemophilia A.

Authors:  T Siegemund; U Scholz; R Schobess; A Siegemund
Journal:  Hamostaseologie       Date:  2014       Impact factor: 1.778

Review 5.  Waveform analysis of clotting test optical profiles in the diagnosis and management of disseminated intravascular coagulation (DIC).

Authors:  C H Toh; A R Giles
Journal:  Clin Lab Haematol       Date:  2002-12

6.  Frequency of abnormal biphasic aPTT clot waveforms in patients with underlying disorders associated with disseminated intravascular coagulation.

Authors:  Takeshi Matsumoto; Hideo Wada; Yukiko Nishioka; Midori Nishio; Yasunori Abe; Junji Nishioka; Yuko Kamikura; Tomohiro Sase; Toshihiro Kaneko; Wim P M Houdijk; Tsutomu Nobori; Hiroshi Shiku
Journal:  Clin Appl Thromb Hemost       Date:  2006-04       Impact factor: 2.389

7.  Specific and global coagulation tests in patients with mild haemophilia A with a double mutation (Glu113Asp, Arg593Cys).

Authors:  Alenka Trampuš Bakija; Maruša Debeljak; Irena Preložnik Zupan; Majda Benedik Dolničar; Jernej Kovač; Janez Jazbec
Journal:  Blood Transfus       Date:  2015-05-15       Impact factor: 3.443

8.  Combination of biphasic transmittance waveform with blood procalcitonin levels for diagnosis of sepsis in acutely ill patients.

Authors:  Ahmed N Zakariah; Simona M Cozzi; Marc Van Nuffelen; Carla Maria Clausi; Olivier Pradier; Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2008-05       Impact factor: 7.598

Review 9.  Acquired hemophilia A: emerging treatment options.

Authors:  Maissaa Janbain; Cindy A Leissinger; Rebecca Kruse-Jarres
Journal:  J Blood Med       Date:  2015-05-08

10.  Usefulness of the second-derivative curve of activated partial thromboplastin time on the ACL-TOP coagulation analyzer for detecting factor deficiencies.

Authors:  Naoki Tokunaga; Chihiro Inoue; Toshiyuki Sakata; Kumiko Kagawa; Masahiro Abe; Norimichi Takamatsu; Takayuki Nakao; Toshio Doi
Journal:  Blood Coagul Fibrinolysis       Date:  2016-06       Impact factor: 1.276

View more
  5 in total

1.  Differences in the Composition of Activated Partial Thromboplastin Time (APTT) Reagents Affect Clot Waveform Analysis.

Authors:  Konami Kato; Yuki Hatayama; Hisashi Shimohiro; Hitomi Ichikawa; Tetsuya Fukuda
Journal:  Yonago Acta Med       Date:  2022-08-29       Impact factor: 1.371

2.  Usefulness of the APTT waveform for the diagnosis of DIC and prediction of the outcome or bleeding risk.

Authors:  Kei Suzuki; Hideo Wada; Takeshi Matsumoto; Makoto Ikejiri; Kohshi Ohishi; Yoshiki Yamashita; Hiroshi Imai; Toshiaki Iba; Naoyuki Katayama
Journal:  Thromb J       Date:  2019-06-28

3.  Clot waveform of APTT has abnormal patterns in subjects with COVID-19.

Authors:  Takuya Shimura; Makoto Kurano; Yoshiaki Kanno; Mahoko Ikeda; Koh Okamoto; Daisuke Jubishi; Sohei Harada; Shu Okugawa; Kyoji Moriya; Yutaka Yatomi
Journal:  Sci Rep       Date:  2021-03-04       Impact factor: 4.379

4.  Update on the Clot Waveform Analysis.

Authors:  Hideo Wada; Takeshi Matsumoto; Kohshi Ohishi; Katsuya Shiraki; Motomu Shimaoka
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

5.  Clot Waveform Analysis Demonstrates Low Blood Coagulation Ability in Patients with Idiopathic Thrombocytopenic Purpura.

Authors:  Hideo Wada; Yuhuko Ichikawa; Minoru Ezaki; Katsuya Shiraki; Isao Moritani; Yoshiki Yamashita; Takeshi Matsumoto; Masahiro Masuya; Isao Tawara; Hideto Shimpo; Motomu Shimaoka
Journal:  J Clin Med       Date:  2021-12-20       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.